NCT02971969View on ClinicalTrials.gov

Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B

CompletedOBSERVATIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

November 6, 2021

Study Completion Date

November 6, 2021

Conditions
Hemophilia B
Trial Locations (5)

32610

UF CRC - Clinical Research Center, Gainesville

72202

Arkansas Children's Hospital, Little Rock

48109-5872

University of Michigan Hospital and Health Systems, Ann Arbor

RG24 9NA

Haemophilia, Haemostasis & Thrombosis Centre, Basingstoke

M13 9WL

Manchester Haemophilia Comprehensive Care Center, Manchester

All Listed Sponsors
lead

Ultragenyx Pharmaceutical Inc

INDUSTRY

NCT02971969 - Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B | Biotech Hunter | Biotech Hunter